Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma

NCT01417000 is registered in ClinicalTrials.gov with Aduro Biotech, Inc. as lead sponsor.

NCT NCT01417000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01417000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Lead sponsor
Aduro Biotech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 21, 2011
Completion date
February 10, 2017
Enrollment
93 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer